Karyopharm Therapeutics To Host Conference Call On June 2 To Discuss Results From Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis And To Follow Dr. Mascarenhas' Oral Presentation Of Results At 2026 ASCO Annual Meeting

뉴스 본문을 불러오고 있어요.

Karyopharm Therapeutics To Host Conference Call On June 2 To Discuss Results From Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis And To Follow Dr. Mascarenhas' Oral Presentation Of Results At 2026 ASCO Annual Meeting | 웨이프 WAPE

Karyopharm Therapeutics To Host Conference Call On June 2 To Discuss Results From Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis And To Follow Dr. Mascarenhas' Oral Presentation Of Results At 2026 ASCO Annual Meeting

기사 요약

관련 종목

댓글 —